| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis
|
Crozier, Jennifer A
|
|
|
21 |
12 |
p. 1611-1619
|
artikel
|
| 2 |
A possible case of palaeopathology of leukaemia from Late Antique southern Italy
|
Tulumello, Giorgia
|
|
|
21 |
12 |
p. 1561-1562
|
artikel
|
| 3 |
ASTRO 2020 virtual meeting
|
Gourd, Katherine
|
|
|
21 |
12 |
p. 1557
|
artikel
|
| 4 |
BELLINI: a renaissance for an era of precision therapy in multiple myeloma
|
Ghobrial, Irene
|
|
|
21 |
12 |
p. 1547-1549
|
artikel
|
| 5 |
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
|
Redman, Mary W
|
|
|
21 |
12 |
p. 1589-1601
|
artikel
|
| 6 |
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer
|
Horita, Nobuyuki
|
|
|
21 |
12 |
p. e545
|
artikel
|
| 7 |
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer – Authors' reply
|
Chouaid, Christos
|
|
|
21 |
12 |
p. e546
|
artikel
|
| 8 |
Correction to Lancet Oncol 2020; 21: 1563–73
|
|
|
|
21 |
12 |
p. e553
|
artikel
|
| 9 |
Correction to Lancet Oncol 2020; 21: 645–54
|
|
|
|
21 |
12 |
p. e553
|
artikel
|
| 10 |
Correction to Lancet Oncol 2020; 21: 1443–54
|
|
|
|
21 |
12 |
p. e553
|
artikel
|
| 11 |
Correction to Lancet Oncol 2020; 21: e519–27
|
|
|
|
21 |
12 |
p. e553
|
artikel
|
| 12 |
Correction to Lancet Oncol 2020; 21: e305–16
|
|
|
|
21 |
12 |
p. e553
|
artikel
|
| 13 |
COVID-19 in patients with cancer
|
Smotherman, Carmen
|
|
|
21 |
12 |
p. e539
|
artikel
|
| 14 |
Deep-learning natural language processing for oncological applications
|
Sorin, Vera
|
|
|
21 |
12 |
p. 1553-1556
|
artikel
|
| 15 |
Drug repurposing in oncology
|
Bouche, Gauthier
|
|
|
21 |
12 |
p. e542
|
artikel
|
| 16 |
Drug repurposing in oncology
|
Frantzi, Maria
|
|
|
21 |
12 |
p. e543
|
artikel
|
| 17 |
Drug repurposing in oncology – Authors' reply
|
Tran, Audrey A
|
|
|
21 |
12 |
p. e544
|
artikel
|
| 18 |
Duration of adjuvant treatment for patients with stage III colon cancer
|
Koopman, Miriam
|
|
|
21 |
12 |
p. 1545-1547
|
artikel
|
| 19 |
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
|
Powles, Thomas
|
|
|
21 |
12 |
p. 1574-1588
|
artikel
|
| 20 |
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
|
André, Thierry
|
|
|
21 |
12 |
p. 1620-1629
|
artikel
|
| 21 |
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial
|
Porras, Carolina
|
|
|
21 |
12 |
p. 1643-1652
|
artikel
|
| 22 |
Enabling hope
|
Dee, Edward Christopher
|
|
|
21 |
12 |
p. e549
|
artikel
|
| 23 |
Essential oncology nursing care along the cancer continuum
|
Young, Annie M
|
|
|
21 |
12 |
p. e555-e563
|
artikel
|
| 24 |
EU4Health budget cut threatens Europe's Beating Cancer Plan
|
Gourd, Elizabeth
|
|
|
21 |
12 |
p. 1558
|
artikel
|
| 25 |
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
|
Rocconi, Rodney P
|
|
|
21 |
12 |
p. 1661-1672
|
artikel
|
| 26 |
Groesbeck Parham
|
Lucas, Catherine
|
|
|
21 |
12 |
p. 1560
|
artikel
|
| 27 |
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions
|
Bennett, Charles L
|
|
|
21 |
12 |
p. e575-e588
|
artikel
|
| 28 |
Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial
|
Poortmans, Philip M
|
|
|
21 |
12 |
p. 1602-1610
|
artikel
|
| 29 |
Internal mammary node irradiation in breast cancer: does benefit outweigh risk?
|
Coles, Charlotte E
|
|
|
21 |
12 |
p. 1541-1543
|
artikel
|
| 30 |
Landmark studies of therapeutic vaccination in cervical and ovarian cancers
|
Rose, Peter G
|
|
|
21 |
12 |
p. 1549-1550
|
artikel
|
| 31 |
Lung cancer control in the UK hit badly by COVID-19 pandemic
|
Gourd, Elizabeth
|
|
|
21 |
12 |
p. 1559
|
artikel
|
| 32 |
No-visitor policies cause anxiety and distress for patients with cancer
|
Nelson, Roxanne
|
|
|
21 |
12 |
p. e554
|
artikel
|
| 33 |
Oncology nursing workforce: challenges, solutions, and future strategies
|
Challinor, Julia M
|
|
|
21 |
12 |
p. e564-e574
|
artikel
|
| 34 |
Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma
|
Procopio, Giuseppe
|
|
|
21 |
12 |
p. 1538-1539
|
artikel
|
| 35 |
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
|
Powles, Thomas
|
|
|
21 |
12 |
p. 1563-1573
|
artikel
|
| 36 |
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial
|
Youn, Jin Won
|
|
|
21 |
12 |
p. 1653-1660
|
artikel
|
| 37 |
Shifting from targeted therapies to personalised treatment in chordoma
|
D'Alessandris, Quintino Giorgio
|
|
|
21 |
12 |
p. e547
|
artikel
|
| 38 |
Shifting from targeted therapies to personalised treatment in chordoma – Authors' reply
|
Jia, Qi
|
|
|
21 |
12 |
p. e548
|
artikel
|
| 39 |
Spontaneous pneumothorax secondary to an endometrial stromal sarcoma
|
Suero-Abreu, Giselle A
|
|
|
21 |
12 |
p. e589
|
artikel
|
| 40 |
Strengthening the global nursing workforce for childhood cancer
|
Sullivan, Courtney E
|
|
|
21 |
12 |
p. 1550-1552
|
artikel
|
| 41 |
The future of liquid biopsy
|
Biswas, Dhruva
|
|
|
21 |
12 |
p. e550
|
artikel
|
| 42 |
The quest for efficient trial designs in precision oncology
|
Schuler, Martin
|
|
|
21 |
12 |
p. 1539-1541
|
artikel
|
| 43 |
The real worth of cancer drugs
|
The Lancet Oncology,
|
|
|
21 |
12 |
p. 1537
|
artikel
|
| 44 |
Time to resume active recommendation of the HPV vaccine in Japan
|
Tanaka, Yusuke
|
|
|
21 |
12 |
p. 1552-1553
|
artikel
|
| 45 |
Treatments for newly diagnosed multiple myeloma: when endurance is interrupted
|
Landgren, Ola
|
|
|
21 |
12 |
p. e540
|
artikel
|
| 46 |
Treatments for newly diagnosed multiple myeloma: when endurance is interrupted – Authors' reply
|
Kumar, Shaji K
|
|
|
21 |
12 |
p. e541
|
artikel
|
| 47 |
Tumour mutational burden in treatment-resistant tumours
|
Nie, Wei
|
|
|
21 |
12 |
p. e551
|
artikel
|
| 48 |
Tumour mutational burden in treatment-resistant tumours – Authors' reply
|
Marabelle, Aurelien
|
|
|
21 |
12 |
p. e552
|
artikel
|
| 49 |
Use of chemotherapy in elderly patients with early-stage triple-negative breast cancer
|
Curigliano, Giuseppe
|
|
|
21 |
12 |
p. 1543-1545
|
artikel
|
| 50 |
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
|
Kumar, Shaji K
|
|
|
21 |
12 |
p. 1630-1642
|
artikel
|
Tijdschrift beschrijving